Search | Clinical Trials Finder

Conditions: Anterior Cruciate Ligament Reconstruction
Interventions: Ropivacaine 0.5%, Percocet 7.5/325, Naprosyn 500 mg; Drug
Lead sponsor: Emory University; Other
Eligibility: Not listed
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Arthritis, Rheumatoid
Interventions: celecoxib, Ibuprofen, Naproxen; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 24,081 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2016
U.S. locations: 871
States / cities: Alabaster, Alabama • Bessemer, Alabama • Birmingham, Alabama + 515 more

Conditions: Osteoarthritis, Osteoarthritis, Hip
Interventions: Naproxcinod, Naproxen, Placebo; Drug
Lead sponsor: NicOx; Industry
Eligibility: 40 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 36
States / cities: Mobile, Alabama • Montgomery, Alabama • Tuscaloosa, Alabama + 33 more

Conditions: Osteoarthritis, Knee
Interventions: Celecoxib, Placebo; Drug · Other
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 388 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 33
States / cities: Birmingham, Alabama • Buena Park, California • Denver, Colorado + 28 more

Conditions: Low Back Pain
Interventions: Naproxen, Placebo, PF-04383119 (RN624); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 38
States / cities: Anniston, Alabama • Birmingham, Alabama • Chandler, Arizona + 30 more

Conditions: Osteoarthritis, Knee, Pain
Interventions: V116517 50-mg tablets, V116517 30-mg tablets, Naproxen 500-mg capsules, Placebo; Drug
Lead sponsor: Purdue Pharma LP; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 18
States / cities: Tucson, Arizona • Boynton Beach, Florida • DeLand, Florida + 13 more

Conditions: Migraine
Interventions: Sumatriptan/Naproxen Sodium, Naproxen Sodium; Drug
Lead sponsor: Cady, Roger, M.D.; Individual
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 2
States / cities: Newport Beach, California • Springfield, Missouri

Conditions: Osteoarthritis
Interventions: Canakinumab, Placebo to canakinumab, Naproxen, Placebo to Naproxen; Biological · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 8
States / cities: Anniston, Alabama • Mesa, Arizona • San Diego, California + 5 more

Conditions: Heterotopic Ossification
Interventions: Naproxen, placebo; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 80 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2022
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Odontalgia
Interventions: Oral placebo, Oral ibuprofen, oral naproxen, oral acetaminophen/hydrocodone + ibuprofen; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Healthy Volunteers
Interventions: Naproxen, PL 3100; Drug
Lead sponsor: PLx Pharma; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Pain, Healthy Volunteers
Interventions: Naproxen (BAYH006689), Placebo Gel, A solution of 0.9% Saline, A solution of 0.2% SLS; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Fair Lawn, New Jersey

Conditions: Gout, Moderate Renal Impairment
Interventions: Febuxostat IR, Febuxostat XR, Febuxostat placebo, Colchicine, Naproxen, Lansoprazole; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 189 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 89
States / cities: Birmingham, Alabama • Muscle Shoals, Alabama • Phoenix, Arizona + 75 more

Conditions: Hematology
Interventions: Naproxen Sodium (Aleve, BAY117031), Acetylsalicylic Acid (Aspirin, BAYE4465); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 117 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Osteoarthritis of the Knee
Interventions: ABT-652, Placebo, Naproxen; Drug
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 40 Years to 75 Years
Enrollment: 322 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 23
States / cities: Chandler, Arizona • Tempe, Arizona • Tucson, Arizona + 20 more

Conditions: Migraine, Tension-type Headache, Primary Headache Disorder
Interventions: Sumatriptan 100 mg, Naproxen; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 401 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 2
States / cities: New York, New York • The Bronx, New York

Conditions: Osteoarthritis
Interventions: CJ-023,423, placebo, naproxen; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 340 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 11
States / cities: Anaheim, California • San Diego, California • Jupiter, Florida + 6 more

Conditions: Gastric Ulcer
Interventions: PN400 (VIMOVO), Diclofenac/Misoprostol; Drug
Lead sponsor: POZEN; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Treatment of Sweet Taste Receptors Without or With an Oral Rinse of Ibuprofen Solution in Healthy Participants, Treatment of Sweet Taste Receptors Without or With an Oral Rinse of Naproxen Solution in Healthy Participants
Interventions: Inhibition of Sweet Taste by Ibuprofen Oral Rinses, Inhibition of Sweet Taste by Naproxen Oral Rinses; Drug
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years to 70 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Post-Traumatic Headache
Interventions: sumatriptan/naproxen sodium, Placebo; Drug
Lead sponsor: Cady, Roger, M.D.; Individual
Eligibility: 18 Years to 65 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 3
States / cities: Springfield, Missouri • Nashville, Tennessee • Temple, Texas

Conditions: Osteoarthritis
Interventions: tanezumab 10 mg, tanezumab 5 mg, naproxen, placebo; Biological · Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 849 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 95
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 69 more

Conditions: Migraine Disorders
Interventions: sumatriptan succinate/naproxen sodium, placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 623 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 52
States / cities: Anniston, Alabama • Tuscaloosa, Alabama • Mesa, Arizona + 48 more

Conditions: Bioavailability
Interventions: Naproxen sodium; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Migraine Disorders
Interventions: Placebo, Combination Product (sumatriptan succinate/naproxen sodium); Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 28
States / cities: Jasper, Alabama • Oceanside, California • San Francisco, California + 25 more

Search by objective public record fields.

Anterior Cruciate Ligament Pain Study

Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen

Efficacy and Safety Study of Naproxcinod in Subjects With Osteoarthritis of the Hip

Safety and Efficacy of Celecoxib Versus Placebo in the Treatment of Knee Osteoarthritis in Patients Who Were Unresponsive to Naproxen and Ibuprofen

RN624 In Adult Patients With Chronic Low Back Pain

Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis (OA) of the Knee

Treximet Trademark (TM) in the Prevention and Modification of Disease Progression in Migraine

To Determine the Safety, Tolerability, Pharmacokinetics and Effect on Pain of a Single Intra-articular Administration of Canakinumab in Patients With Osteoarthritis in the Knee

Influence of Naproxen on Heterotropic Bone Formation Following Hip Arthroscopy

Local Anesthesia and Analgesics in Endodontic Pain

Oral Bioequivalence Study of PL 3100 and Naproxen in Healthy Adults

A Study to Learn About Whether BAYH006689 Causes Skin Irritation When Applied as a Topical Gel in Healthy Participants

Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout and Moderate Renal Impairment

Naproxen Sodium/ASA Platelet Study

A Study of ABT-652 in Adults With Osteoarthritis Pain of the Knee

Comparing Naproxen to Sumatriptan for Emergency Headache Patients

A Study Of The Effect Of CJ-023,423 On The Incidence Of Stomach Ulcers

Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers in High Risk Subjects Compared to Arthrotec

Ibuprofen Inhibits Human Sweet Taste

Treximet for Prevention of Post Traumatic Headache Associated With Cognitive Dysfunction

Tanezumab in Osteoarthritis of the Hip or Knee (2)

Study Of Treximet, Formerly Known as Trexima, In The Acute Treatment Of Multiple Migraine Attacks

Fast & Fed Pharmacokinetic (PK) Study

A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 2 of 2)